Rheumatoid arthritis
Conditions
Interventions
RA:the experimental group:MTX 10-15mg po qw+BiQi Capsule, 1.2g po bid
RA:the control group:MTX 10-15mg po qw+LEF, 10mg, po, bid
OA:The traditional Chinese group:BiQi Capsule, 1.2g po bid+Celecoxib capsules 0.2g po take as needed
OA:The western medicine control group:Calcitriol Soft Capsules 0.25ug, po, bid+Celecoxib capsules 0.2g po take as needed
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. RA is confirmed by 2009 ACR Criteria; Imaging results suggest Class I, II or III disease (according to the 1987 American Rheumatism Association (ARA) classification standard); CM inclusion criteria: according to the syndrome of wind and damp stagnation syndrome, or cold and damp stagnation, or phlegm and stasis stagnation, or deficiency of Qi and Blood; 2. Patients aged between 18 and 65 years; 3. Volunteered for the research and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Imaging results suggest Class IV disease (according to the ARA classification standard); 2. Used in the last month or using glucocorticoids, MTX, hydroxychloroquine, willow nitrogen sulfanilamide pyridine, cyclophosphamide, penicillamine and gold preparations and other immunosuppressive drugs or slow-acting drugs; 3. Participating in another clinical trial; 4. Researchers of this study; 5. Unwilling to comply with treatment or assessment regimen; 6. Unable to comply with treatment or assessment regimen; 7. Severe extra-articular diseases like renal amyloidosis, constrictive pericarditis and so on; 8. Severe comorbid conditions likely to compromise follow up evaluation; 9. Complicated with active gastrointestinal diseases or diagnosed with esophagus or digestive ulcer in the last month; 10. Women currently pregnant, or who are planning on becoming pregnant during the study period; 11. Patients with mental disease; 12. Not suitable to enter this research in the view of the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Sharp-van der Heijde;ACR20;Erythrocyte Sedimentation Rate;C Reactive Protein;DAS28;Blood Routine Test;Nrine Routine Test;Feces Rountine Test;ALT;BUN;Rheumatoid Factor;Matrix metalloproteinase 3;Osteoprotegerin;Receptor Activator for Nuclear Factor-? B Ligand;Digital Radiography with both hands;Electrocardiogram;Bone Mineral Density;Chest Digital Radiography; | — |
Countries
China
Contacts
Public ContactQingchun Huang
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed